AbbVie: Dividend Discount Model Suggests Large Valuation Risks (NYSE:ABBV)

September 29, 2024

AbbVie reported mixed Q2 2024 results. Looking ahead, I see continued pressure for Humira sales and increasing in-house R&D expenses. Find out why ABBV stock is a Sell.

Search

RECENT PRESS RELEASES

Bitcoin And Wall Street: The Correlation Reaches An Unprecedented Level!

SWI Editorial Staff2024-09-29T07:54:54-07:00September 29, 2024|

Jasmy, Daddy Tate, Reef lead losses as Bitcoin stalls at $65k

SWI Editorial Staff2024-09-29T07:54:52-07:00September 29, 2024|

Polymarket Predicts 61% Chance of 2024 Bitcoin All-Time High, 17% for $100K

SWI Editorial Staff2024-09-29T07:54:50-07:00September 29, 2024|

Bitcoin retail comeback on the cards as Coinbase pierces top-400 apps

SWI Editorial Staff2024-09-29T07:54:48-07:00September 29, 2024|

Documents reveal ‘chronic threat’ posed by firefighting foam despite environmental agency’s decades-long notice: ‘A missed opportunity’

SWI Editorial Staff2024-09-29T07:54:06-07:00September 29, 2024|

This Book Helped Save the Planet—but Created a Very Harmful Myth

SWI Editorial Staff2024-09-29T07:54:04-07:00September 29, 2024|